ArticleNature microbiology2022
Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing.
Article in Nature microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 111 citations in OpenAlex.
- A bifunctional RNase H protein supports DNA replication and transcription in nucleus-formingbioRxiv : the preprint server for biology · 2026Article
- Defining the essential genome of diverse phages with phage Tn-seq.Nature microbiology · 2026Article
- Systematic mapping of bacteriophage gene essentiality with HIDEN-SEQ.Nature microbiology · 2026Article
- From Cloning Vectors to Phage Display: Engineering Principles and Translational Applications of Bacteriophage Display Platforms.International journal of molecular sciences · 2026Review
- Phage as a prospective arsenal against superbugs.Molecular biology reports · 2026Review
- De novo design of potent CRISPR-Cas13 inhibitors.Nature chemical biology · 2026Article
- Bacteriophage-Based Therapeutic, Diagnostic, and Biocontrol Platforms: Engineering, Evidence, and Translational Challenges.International journal of molecular sciences · 2026Review
- Article
- A structural accessibility principle for LbuCas13a activation by noncontiguous DNA.Nucleic acids research · 2026Article
- Beyond DNA editing: how Cas13 redefined programmable RNA manipulation and what still limits its therapeutic promise.Nucleic acids research · 2026Review
- Functional diversity of phage sponge proteins that sequester host immune signals.Nature microbiology · 2026Article
- DUSP11 is an RNA triphosphatase that limits PspCas13b activity by destabilizing gRNA abundance in mammalian cells.Nucleic acids research · 2026Article
- Phage homing endonuclease amplifies anti-defense genes to evade bacterial immunity.Nature communications · 2026Article
- A phage-encoded sponge protein suppresses bacterial TIR-Caspase immune signaling.Nature communications · 2026Article
- The phage nucleus synergizes with an anti-defense protein to resist bacterial immunity.Cell reports · 2026Article
- Rage against the mean: a perspective on measuring fitness of individual phage particles.Npj viruses · 2026Review
- Cross-order detection of bacteriophage transduction in microbial communities using RNA barcoding.Nature communications · 2026Article
- Review
- Occurrence and applications of CRISPR-Cas systems in bifidobacteria.Applied and environmental microbiology · 2026Review
- Engineering bacteriophages for gut health: precision antimicrobials and beyond.Journal of nanobiotechnology · 2026Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
CRISPR-Cas13 proteins are RNA-guided RNA nucleases that defend against incoming RNA and DNA phages by binding to complementary target phage transcripts followed by general, non-specific RNA degradation. Here we analysed the defensive capabilities of LbuCas13a from Leptotrichia buccalis and found it to have robust antiviral activity unaffected by target phage gene essentiality, gene expression timing or target sequence location. Furthermore, we find LbuCas13a antiviral activity to be broadly effective against a wide range of phages by challenging LbuCas13a against nine E. coli phages from diverse phylogenetic groups. Leveraging the versatility and potency enabled by LbuCas13a targeting, we applied LbuCas13a towards broad-spectrum phage editing. Using a two-step phage-editing and enrichment method, we achieved seven markerless genome edits in three diverse phages with 100% efficiency, including edits as large as multi-gene deletions and as small as replacing a single codon. Cas13a can be applied as a generalizable tool for editing the most abundant and diverse biological entities on Earth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.